Bevacizumab, aflibercept, and regorafenib are antiangiogenic drugs currently approved for mCRC treatment. These drugs have proved successful for the clinical treatment of various types of cancer and their mechanism of action results different affecting a variable range of cell types and signaling within tumor microenvironment.
|Drug ||Indication ||Mechanism of action |
|Bevacizumab ||First-/second-line mCRC plus CT ||MoAb binding VEGF-A |
|Aflibercept ||Second-line mCRC plus FOLFIRI ||VEGF decoy binding VEGF-A, VEGF-B, and PlGF |
|Regorafenib ||Third-line mCRC as single agent ||Multikinase inhibitor of RTKI of VEGFR-2 and -3, TIE-2, PDGFR, FGFR, RET, and c-kit |